Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
Abstract Background Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown significant responses in refra...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-12-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40164-017-0092-3 |
| _version_ | 1819083122830999552 |
|---|---|
| author | Mauricio Sarmiento Maldonado Pablo Ramírez Villanueva Pablo Bertín Cortes-Monroy Veronica Jara Arias Katherine Soto Donoso Pablo Uribe Gonzalez Mauricio Ocqueteau Tachini Jose Antonio Perez-Simón |
| author_facet | Mauricio Sarmiento Maldonado Pablo Ramírez Villanueva Pablo Bertín Cortes-Monroy Veronica Jara Arias Katherine Soto Donoso Pablo Uribe Gonzalez Mauricio Ocqueteau Tachini Jose Antonio Perez-Simón |
| author_sort | Mauricio Sarmiento Maldonado |
| collection | DOAJ |
| description | Abstract Background Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown significant responses in refractory GVHD patients. Cases presentation In this report we present our experience in 8 patients with acute or chronic GVHD with refractoriness to steroids and extracorporeal photopheresis treated with ruxolitinib. Three patients had acute GVHD (1 pulmonary, 2 cutaneous, 1 multi-systemic) and 5 had chronic GVHD (3 cutaneous); 85% obtained an overall response and 50% a complete response with a tolerable toxicity profile. Conclusions In our series, Ruxolitinib was very active as a rescue therapy for patients with acute or chronic GVHD refractory to standard treatment. |
| first_indexed | 2024-12-21T20:27:33Z |
| format | Article |
| id | doaj.art-7840b2d58f9743b79988cbc36a8f2f07 |
| institution | Directory Open Access Journal |
| issn | 2162-3619 |
| language | English |
| last_indexed | 2024-12-21T20:27:33Z |
| publishDate | 2017-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Experimental Hematology & Oncology |
| spelling | doaj.art-7840b2d58f9743b79988cbc36a8f2f072022-12-21T18:51:20ZengBMCExperimental Hematology & Oncology2162-36192017-12-01611910.1186/s40164-017-0092-3Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresisMauricio Sarmiento Maldonado0Pablo Ramírez Villanueva1Pablo Bertín Cortes-Monroy2Veronica Jara Arias3Katherine Soto Donoso4Pablo Uribe Gonzalez5Mauricio Ocqueteau Tachini6Jose Antonio Perez-Simón7Adult Hematopoietic Stem Cell Transplantation Program, Pontificia Universidad Católica de ChileSchool of Medicine, Universidad Austral de ChileAdult Hematopoietic Stem Cell Transplantation Program, Pontificia Universidad Católica de ChileAdult Hematopoietic Stem Cell Transplantation Program, Pontificia Universidad Católica de ChileAdult Hematopoietic Stem Cell Transplantation Program, Pontificia Universidad Católica de ChileAdult Hematopoietic Stem Cell Transplantation Program, Pontificia Universidad Católica de ChileAdult Hematopoietic Stem Cell Transplantation Program, Pontificia Universidad Católica de ChileDepartment of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC)Abstract Background Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown significant responses in refractory GVHD patients. Cases presentation In this report we present our experience in 8 patients with acute or chronic GVHD with refractoriness to steroids and extracorporeal photopheresis treated with ruxolitinib. Three patients had acute GVHD (1 pulmonary, 2 cutaneous, 1 multi-systemic) and 5 had chronic GVHD (3 cutaneous); 85% obtained an overall response and 50% a complete response with a tolerable toxicity profile. Conclusions In our series, Ruxolitinib was very active as a rescue therapy for patients with acute or chronic GVHD refractory to standard treatment.http://link.springer.com/article/10.1186/s40164-017-0092-3RuxolitinibGraft versus host diseaseCorticoid refractorinessExtracorporeal photopheresis |
| spellingShingle | Mauricio Sarmiento Maldonado Pablo Ramírez Villanueva Pablo Bertín Cortes-Monroy Veronica Jara Arias Katherine Soto Donoso Pablo Uribe Gonzalez Mauricio Ocqueteau Tachini Jose Antonio Perez-Simón Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis Experimental Hematology & Oncology Ruxolitinib Graft versus host disease Corticoid refractoriness Extracorporeal photopheresis |
| title | Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis |
| title_full | Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis |
| title_fullStr | Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis |
| title_full_unstemmed | Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis |
| title_short | Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis |
| title_sort | compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis |
| topic | Ruxolitinib Graft versus host disease Corticoid refractoriness Extracorporeal photopheresis |
| url | http://link.springer.com/article/10.1186/s40164-017-0092-3 |
| work_keys_str_mv | AT mauriciosarmientomaldonado compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis AT pabloramirezvillanueva compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis AT pablobertincortesmonroy compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis AT veronicajaraarias compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis AT katherinesotodonoso compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis AT pablouribegonzalez compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis AT mauricioocqueteautachini compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis AT joseantonioperezsimon compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis |